Compare Microchip Technology Inc. (MCHP) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Microchip Technology Inc. vs TransMedics Group Inc — how do they compare? Microchip Technology Inc. trades at $74.31 (market cap $41.01B), while TransMedics Group Inc trades at $77.47 (market cap $2.74B). The key difference: Microchip Technology Inc. is far larger — about 15× TransMedics Group Inc's market cap, and Microchip Technology Inc. pays a 2.41% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Microchip Technology Inc. for 62 Days and TransMedics Group Inc for 24 Days on average.
| MCHP | TMDX | |
|---|---|---|
Market Cap | $41.01B | $2.74B |
Volume | 9,972,516 | 949,331 |
Sector | Technology | Health |
52-Week High | $102.97 | $150.42 |
52-Week Low | $49.02 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $46.13B | $3.13B |
Dividend Yield | 2.41% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Microchip Technology (MCHP) trades at $74.00, down 5.15% over 24 hours amid a bearish technical signal. The company reported a net loss of -$500,000 in 2025, a sharp decline from prior profitability, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion in Ethernet and 48V power portfolios and the completion of the Hailo acquisition, targeting growth in automotive, industrial, and AI-driven data center markets.
Outlook: Strong analyst consensus (69.57% Buy) and a $110.50 price target suggest significant upside potential, driven by AI infrastructure demand and portfolio expansion. Key risks include high valuation multiples, substantial long-term debt of $5.63B, and sensitivity to semiconductor cycle volatility. Earnings recovery in 2026 forecasts is critical for sustaining investor confidence.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Microchip Technology Inc.
Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
